<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(1)</volume><submitter>Park J</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>This study aimed to evaluate incidence risk and adverse clinical outcomes in COVID-19 disease among short-term users of acid-suppressants in South Korea.&lt;h4>Methods&lt;/h4>This retrospective cohort study, conducted using a nationwide claims database for South Korea, used data from patients with COVID-19 tested between January 1 and May 15, 2020. Patients aged over 18 years and prescribed proton pump inhibitors (PPI) or histamine-2 receptor antagonist (H&lt;sub>2&lt;/sub>RA) for more than 7 days were identified. Primary outcome was COVID-19 while secondary outcomes were all-cause mortality, hospitalization with respiratory disease, or intensive respiratory intervention. Large-scale propensity scores were used to match patients, while the Cox proportional hazard model was utilized </pubmed_abstract><journal>BMC pharmacology &amp; toxicology</journal><pagination>9</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8762632</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.</pubmed_title><pmcid>PMC8762632</pmcid><pubmed_authors>You SC</pubmed_authors><pubmed_authors>Shin WG</pubmed_authors><pubmed_authors>Park J</pubmed_authors><pubmed_authors>Cho J</pubmed_authors><pubmed_authors>In Seo S</pubmed_authors><pubmed_authors>Park CH</pubmed_authors><pubmed_authors>Park RW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.</name><description>&lt;h4>Background&lt;/h4>This study aimed to evaluate incidence risk and adverse clinical outcomes in COVID-19 disease among short-term users of acid-suppressants in South Korea.&lt;h4>Methods&lt;/h4>This retrospective cohort study, conducted using a nationwide claims database for South Korea, used data from patients with COVID-19 tested between January 1 and May 15, 2020. Patients aged over 18 years and prescribed proton pump inhibitors (PPI) or histamine-2 receptor antagonist (H&lt;sub>2&lt;/sub>RA) for more than 7 days were identified. Primary outcome was COVID-19 while secondary outcomes were all-cause mortality, hospitalization with respiratory disease, or intensive respiratory intervention. Large-scale propensity scores were used to match patients, while the Cox proportional hazard model was utilized </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2025-04-18T13:45:01.535Z</modification><creation>2022-02-11T15:25:49.244Z</creation></dates><accession>S-EPMC8762632</accession><cross_references><pubmed>35039078</pubmed><doi>10.1186/s40360-022-00549-7</doi></cross_references></HashMap>